HUE064734T2 - 1-((2-(2,2,2-trifluoretoxi)piridin-4-il)metil)karbamid származékok mint KCNQ potenciátorok - Google Patents
1-((2-(2,2,2-trifluoretoxi)piridin-4-il)metil)karbamid származékok mint KCNQ potenciátorokInfo
- Publication number
- HUE064734T2 HUE064734T2 HUE20709409A HUE20709409A HUE064734T2 HU E064734 T2 HUE064734 T2 HU E064734T2 HU E20709409 A HUE20709409 A HU E20709409A HU E20709409 A HUE20709409 A HU E20709409A HU E064734 T2 HUE064734 T2 HU E064734T2
- Authority
- HU
- Hungary
- Prior art keywords
- kcnq
- potentiators
- trifluoroethoxy
- pyridin
- methyl
- Prior art date
Links
- VDRSSRINXUQZRZ-UHFFFAOYSA-N [2-(2,2,2-trifluoroethoxy)pyridin-4-yl]methylurea Chemical class FC(COC1=NC=CC(=C1)CNC(=O)N)(F)F VDRSSRINXUQZRZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962801716P | 2019-02-06 | 2019-02-06 | |
US201962811038P | 2019-02-27 | 2019-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE064734T2 true HUE064734T2 (hu) | 2024-04-28 |
Family
ID=69743945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE20709409A HUE064734T2 (hu) | 2019-02-06 | 2020-02-04 | 1-((2-(2,2,2-trifluoretoxi)piridin-4-il)metil)karbamid származékok mint KCNQ potenciátorok |
Country Status (22)
Country | Link |
---|---|
US (3) | US11208383B2 (hu) |
EP (1) | EP3921030B1 (hu) |
JP (2) | JP7451543B2 (hu) |
KR (1) | KR20210126040A (hu) |
CN (1) | CN113692304A (hu) |
AU (1) | AU2020218180A1 (hu) |
BR (1) | BR112021015544A2 (hu) |
CA (1) | CA3128975A1 (hu) |
DK (1) | DK3921030T3 (hu) |
ES (1) | ES2968807T3 (hu) |
FI (1) | FI3921030T3 (hu) |
HR (1) | HRP20240012T1 (hu) |
HU (1) | HUE064734T2 (hu) |
IL (1) | IL285113A (hu) |
LT (1) | LT3921030T (hu) |
MX (1) | MX2021009396A (hu) |
PL (1) | PL3921030T3 (hu) |
PT (1) | PT3921030T (hu) |
RS (1) | RS65040B1 (hu) |
SG (1) | SG11202108599SA (hu) |
SI (1) | SI3921030T1 (hu) |
WO (1) | WO2020163268A1 (hu) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3921030T (lt) * | 2019-02-06 | 2024-01-25 | Eli Lilly And Company | 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai |
AR122739A1 (es) | 2020-06-25 | 2022-10-05 | Idorsia Pharmaceuticals Ltd | Derivados de ciclobutil-urea |
TW202330471A (zh) * | 2021-09-30 | 2023-08-01 | 日商住友製藥股份有限公司 | 環丙醯胺衍生物 |
AU2022390453A1 (en) | 2021-11-19 | 2024-05-30 | F. Hoffmann-La Roche Ag | Novel heteroaryl-urea compounds as kv7.2 inhibitors |
WO2023091461A1 (en) | 2021-11-19 | 2023-05-25 | Icagen, Llc | Pyridine compounds as kv7.2 enhancers |
WO2023121992A1 (en) | 2021-12-22 | 2023-06-29 | Icagen, Llc | Cyclopropyl compounds |
WO2023158584A1 (en) | 2022-02-15 | 2023-08-24 | Icagen, Llc | New bicyclopentane derivatives |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005100349A2 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
CN103709097A (zh) | 2012-09-28 | 2014-04-09 | 中国科学院上海药物研究所 | 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用 |
WO2014145028A2 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
JP6577479B2 (ja) | 2014-02-27 | 2019-09-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Nav チャンネル阻害剤としてのヘテロ環化合物及びその使用 |
EP3210969B1 (en) | 2014-10-24 | 2021-04-28 | ONO Pharmaceutical Co., Ltd. | Kcnq2-5 channel activator |
ES2866324T3 (es) | 2016-04-22 | 2021-10-19 | Ono Pharmaceutical Co | Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria |
LT3921030T (lt) * | 2019-02-06 | 2024-01-25 | Eli Lilly And Company | 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai |
-
2020
- 2020-02-04 LT LTEPPCT/US2020/016499T patent/LT3921030T/lt unknown
- 2020-02-04 EP EP20709409.5A patent/EP3921030B1/en active Active
- 2020-02-04 SI SI202030316T patent/SI3921030T1/sl unknown
- 2020-02-04 WO PCT/US2020/016499 patent/WO2020163268A1/en active Application Filing
- 2020-02-04 HU HUE20709409A patent/HUE064734T2/hu unknown
- 2020-02-04 PL PL20709409.5T patent/PL3921030T3/pl unknown
- 2020-02-04 US US16/781,148 patent/US11208383B2/en active Active
- 2020-02-04 CA CA3128975A patent/CA3128975A1/en active Pending
- 2020-02-04 HR HRP20240012TT patent/HRP20240012T1/hr unknown
- 2020-02-04 MX MX2021009396A patent/MX2021009396A/es unknown
- 2020-02-04 AU AU2020218180A patent/AU2020218180A1/en active Pending
- 2020-02-04 RS RS20240009A patent/RS65040B1/sr unknown
- 2020-02-04 ES ES20709409T patent/ES2968807T3/es active Active
- 2020-02-04 CN CN202080012797.0A patent/CN113692304A/zh active Pending
- 2020-02-04 KR KR1020217028040A patent/KR20210126040A/ko unknown
- 2020-02-04 BR BR112021015544-9A patent/BR112021015544A2/pt unknown
- 2020-02-04 DK DK20709409.5T patent/DK3921030T3/da active
- 2020-02-04 FI FIEP20709409.5T patent/FI3921030T3/fi active
- 2020-02-04 JP JP2021546360A patent/JP7451543B2/ja active Active
- 2020-02-04 SG SG11202108599SA patent/SG11202108599SA/en unknown
- 2020-02-04 PT PT207094095T patent/PT3921030T/pt unknown
-
2021
- 2021-07-25 IL IL285113A patent/IL285113A/en unknown
- 2021-11-19 US US17/531,000 patent/US11840516B2/en active Active
-
2023
- 2023-11-09 US US18/388,299 patent/US20240076269A1/en active Pending
-
2024
- 2024-03-06 JP JP2024033668A patent/JP2024063191A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220073464A1 (en) | 2022-03-10 |
PT3921030T (pt) | 2024-01-12 |
JP7451543B2 (ja) | 2024-03-18 |
DK3921030T3 (da) | 2024-01-02 |
US11840516B2 (en) | 2023-12-12 |
RS65040B1 (sr) | 2024-02-29 |
HRP20240012T1 (hr) | 2024-03-29 |
LT3921030T (lt) | 2024-01-25 |
WO2020163268A1 (en) | 2020-08-13 |
MX2021009396A (es) | 2021-09-10 |
PL3921030T3 (pl) | 2024-05-06 |
BR112021015544A2 (pt) | 2021-10-26 |
SI3921030T1 (sl) | 2024-03-29 |
FI3921030T3 (fi) | 2024-01-08 |
EP3921030B1 (en) | 2023-10-11 |
EP3921030A1 (en) | 2021-12-15 |
SG11202108599SA (en) | 2021-09-29 |
AU2020218180A1 (en) | 2021-08-19 |
US11208383B2 (en) | 2021-12-28 |
KR20210126040A (ko) | 2021-10-19 |
CA3128975A1 (en) | 2020-08-13 |
ES2968807T3 (es) | 2024-05-14 |
JP2022519744A (ja) | 2022-03-24 |
US20200247752A1 (en) | 2020-08-06 |
IL285113A (en) | 2021-09-30 |
CN113692304A (zh) | 2021-11-23 |
US20240076269A1 (en) | 2024-03-07 |
JP2024063191A (ja) | 2024-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285113A (en) | History of 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea as kcnq enhancers | |
DK3833670T3 (da) | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorphenyl)-2-methylpyrimidin-4(3h)-on-derivater og lignende forbindelser som PTPN11- (SHP2) hæmmere til cancerbehandling | |
EP4077311A4 (en) | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION PROCESSES AND THEIR USES | |
ATE516272T1 (de) | 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one | |
EP3376865A4 (en) | 4 - ((6- (2,4-difluorophenyl) -1,1-difluoro-2-HYDROXY-3- (1 H | |
EP1954683A4 (en) | 2- (PHENYL OR HETEROCYCLIC) -1H-PHENANTRHO (9,10-D) IMIDAZOLES AS INHIBITORS OF MPGES-1 | |
IL252844B (en) | Process for preparing 4-(3-(-6-cyano-5-(trifluoromethyl)pyridin-3-yl)-4-oxo-2-thio-3,1-diazaspiro[5,4]-octan-1-yl) -2- fluoro-n-methylbenzamide | |
IL268690A (en) | (4)- 1-(1-(S-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(1-methyl-H1-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridine-2 (H1)-Onat salts and their crystalline structures and pharmaceutical preparations containing them | |
MX2016012687A (es) | Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central. | |
IL289951A (en) | A urea compound as an lpa1 receptor antagonist | |
EP4194449A4 (en) | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | |
EP3927696C0 (en) | CRYSTALLINE FORM OF 1-(1-OXO-1,2-DIHYDROISOCINOLINE-5-YL)-5-(TRIFLUORMETHYL)-(2-(TRIFLUORMETHYL)PYRIDINE-4-YL)-1H-PYRAZOLE-4-CARBOXAMIDE MONOHYDRATE | |
IL220851A (en) | Process for the preparation of n - (2 - (2 - (4 - (2 - (7,6-dimethoxy-4,3-dihydro-iso-quinoline-2 - (1 h))) ethyl) phenyl) - h2 - tetrazole - 5-ram (5,4-dimethoxyphenyl) -4-oxo-h4-chromium-2-carboxamide methane-sulfonate, its intermediate and intermediate preparation process | |
IL255224B (en) | Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate | |
MX2018006329A (es) | Agente terapeutico para cancer de mama. | |
DK3720438T3 (da) | Svampedræbende midler, der er afledt af heterocyklus-substitueret pyridin | |
SI3559010T1 (sl) | Postopek za pripravo 5-((4-(2-(5-(1-hidroksietil)-2-piridinil)etoksi) fenil)metil)-2,4-tiazolidindiona in soli le-tega | |
EP4137483A4 (en) | HETEROCYCLIC BENZONITRIC COMPOUND, PREPARATION METHOD AND USE THEREOF | |
MA49068A (fr) | Composé n-(4-pyridyl) nicotinamide ou sel de celui-ci | |
DK3456712T3 (da) | Hidtil ukendte 2,4,6-trisubstitueret S-triazinforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
SI3292133T1 (sl) | Postopek priprave 2-(4-(2-(((2-(4-klorofenil)-1,3-tiazol-4-il)metil)sulfanil)-3,5-dician- 6-(pirolidin-1-il)piridin-4-il)fenoksi)etil-L-alanil-L-alaninat hidroklorida | |
DK3810089T3 (en) | Vandig formulering omfattende 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | |
DK3947711T3 (da) | Urinstofbiosensorer, der er stabiliseret ved rumtemperatur | |
EP3733661A4 (en) | COMPOS &XC9; DE D &XC9; RIV &XC9; 2 - [5 -IMIDAZOLE - &XFF11; -YLM &XC9; THYL) PYRIDINE- &XFF13; -YL] BENZIMIDAZOLE, AND M &XC9; DICAMENT CONTAINING THIS ONE | |
EP3541797A4 (en) | 4 - ((6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H |